Print this page    •   Back to Web version of article

Vaccine Against Three Kinds of HIV Begins Human Tests

November 22, 2002

The new Vaccine Research Center at the U.S. National Institute of Allergy and Infectious Diseases is starting the first human trial of its vaccine candidate, developed to target HIV clades (subtypes) A, B, and C. Together these subtypes are responsible for about 90 percent of the world's AIDS epidemic (clade B causes almost all of the infections in the U.S.). Also, it might be more difficult for HIV to develop mutations to escape control by a multiclade vaccine, since it targets the virus in different ways.

Fifty healthy HIV-negative volunteers between 18 and 40 are needed for the first trial, which will be conducted at the National Institutes of Health in Bethesda, Maryland. This placebo-controlled trial will check for safety and also for immune responses to HIV. Later trials will run in several U.S. sites, as well as in Haiti and South Africa.

For more information about the trial, including ways to volunteer, call 1-866-833-LIFE (5433), email, or visit: or

ISSN # 1052-4207

Copyright 2002 by John S. James. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.

Back to the AIDS Treatment News November 22, 2002 contents page.

This article was provided by AIDS Treatment News. It is a part of the publication AIDS Treatment News. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.